Biogen
BIIB
947 hedge funds and large institutions have $49.3B invested in Biogen in 2016 Q1 according to their latest regulatory filings, with 95 funds opening new positions, 364 increasing their positions, 350 reducing their positions, and 103 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 364 | Existing positions reduced: 350
7% less call options, than puts
Call options by funds: $1.05B | Put options by funds: $1.13B
8% less first-time investments, than exits
New positions opened: 95 | Existing positions closed: 103
2% less funds holding
Funds holding: 969 → 947 (-22)
14% less funds holding in top 10
Funds holding in top 10: 37 → 32 (-5)
16% less capital invested
Capital invested by funds: $58.9B → $49.3B (-$9.59B)
Top Buyers
Top Sellers
BIIB Hedge Fund Activity: Q1 2016 in Review
947 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2016, worth a combined $49.3B — down 16% from $58.9B a quarter earlier.
Sellers outnumbered buyers: 103 funds closed out of BIIB and 95 opened new positions — a net loss of 8 holders — while 350 trimmed existing stakes and 364 added.
The largest buyer was Royal London Asset Management, adding an estimated $3.73B. The largest seller was Wellington Management Group, cutting an estimated $164M.
- 947 institutional investors held Biogen (BIIB) as of Q1 2016, down from 969 in Q4 2015.
- Funds reported $49.3B of Biogen stock for Q1 2016, down 16% quarter-over-quarter.
- 95 funds opened new Biogen positions in Q1 2016 and 103 closed out, a net change of -8 holders.
- The largest Biogen buyer in Q1 2016 was Royal London Asset Management, an estimated $3.73B added.
- The largest Biogen seller in Q1 2016 was Wellington Management Group, an estimated $164M sold.
Based on aggregated 13F filings for Q1 2016.